For decades, scientists have complained that federally provided cannabis is of inferior quality and that it is not representative of the products available in state-legal markets.
Archives: News Releases
Since 1992, every Thursday and when breaking news warrants, NORML | The NORML Foundation have been issuing weekly press releases for marijuana law supporters and the media.
NORML’s News Releases archives goes back to 1996 and serves as a valuable tool to alert citizens about cannabis-related news and legislation as well as a research tool for reviewing a chronology of marijuana law reform.
Investigators concluded, “[O]ur findings failed to find evidence that legalization of commercial marijuana was associated with any significant change in entry into marijuana‐related treatment services.”
“Consumers paid more for dried flower in illegal, medical, and recreational states without stores, than recreational states with stores,” researchers concluded.
Forty-four percent of respondents said that they opposed “allowing employers to test workers for marijuana in states where [it] is legal.”
Justices determined, “Because the use of marijuana under AMMA ‘must be considered the equivalent of the use of any other medication,’ … the exposure of [the plaintiff’s] infant to marijuana … did not constitute neglect.”
Support was strongest (83 percent) among Democrats and those between the ages of 30 to 44.
Under current regulations, the DEA is primarily tasked with licensing marijuana cultivators, as well as granting Schedule I licenses to scientists wishing to study cannabis in clinical settings.
Their analysis predicts that several additional states – including Florida, Missouri, and Ohio – will regulate adult use markets in the coming years.